FundraiseNov 9, 2026, 12:48 UTC

Vesalius Longevity Labs raises $6.5M, led by Equinox chairman Harvey Spevak

What's the deal? Vesalius Longevity Labs, a peptide and longevity company, has closed a $6.5 million private placement led by an investor group organized by Harvey Spevak, chairman of Equinox Group. The company sold 6,190,475 units at $1.05 each, each pairing one common share with half a share-purchase warrant.

What's the endgame? Vesalius connects licensed healthcare providers with peptide therapeutics through what it calls a "B2Doctor2Consumer" model. It plans to use the proceeds to expand its sales team and enter new markets.

Why now? The financing follows Vesalius's reverse takeover of Sweet Earth Holdings, which gives the venture a public-market vehicle set to trade on the Canadian Securities Exchange under the ticker "VLAB." The new funds provide early capital as it builds out its platform.

What's Spevak bringing? Spevak has more than three decades of experience building consumer brands. "I believe longevity represents one of the most exciting opportunities in health and wellness over the coming decade," he said.

What could go wrong? At $6.5 million, the round is modest against a broader wave of longevity investment — NewLimit raised $435 million in June to push a medicine toward human trials. The announcement alone does not establish comparable scientific or clinical progress; its significance will hinge on how the money is spent.

The signal: Spevak's backing signals that consumer-wellness capital is flowing toward longevity, bridging lifestyle brands and clinical therapeutics. Whether Vesalius can convert that interest into evidence for its peptide business remains the open question.